

Case presentations



- 77 year old female patient diagnosed in 6/2012 with right sided T3N1 colon cancer
 - Resection and adjuvant Capecitabine
- 1/2014 had rising CEA and several pelvic and intraabdominal metastasis
 - 5FU/ bevacizumab until 2016 had progression
 - FOLFOX/ Bev from 2/2016 until 6/2016 with very good response
 - Developed allergic reaction to oxaliplatin
 - Started on FOLFIRI / Bev 7/2016
 - 11/2017 progression tested for KRAS found to be wildtype started on FOLFIRI Cetuximab
 - Progression in 6/2018- started on Lonsurf
 - Progressed on 8/2018
- ECOG PS 1
- Imaging- multiple liver, lung and peritoneal lesions

- Next step(s)
 - Re-challenge with FOLFOX Bev (de-sensitization)
 - Regorafenib
 - Clinical trial
 - Other therapeutic options
 - Other testing

Companion Diagnostic (CDx) Associated Findings

GENOMIC FINDINGS DETECTED

KRAS wildtype (codons 12 & 13)

Erbitux® (Cetuximab)

KRAS/NRAS

Vectibix® (Panitumumab)

wildtype (codons 12, 13, 59, 61, 117, & 146 in exons 2, 3, & 4)

OTHER ALTERATIONS & BIOMARKERS IDENTIFIED

Results reported in this section are not prescriptive or conclusive for labeled use of any specific therapeutic product. See professional services section for additional information.

Microsatellite status MSI-High §

Tumor Mutational Burden 78 Muts/Mb §

ASXL1 G645fs*58

ATR ATR(NM_001184) inversion intron 34 - intron 35 \$

BRAF V600E

CDH1 P126fs*89

CDH1 P127fs*41

CDH1 R598*

DNMT3A R882H

FAM123B G171fs*38

GNAS R201H

HNF1A P291fs*51

MLL2 P998fs*2

MSH3 K383fs*32

PIK3R1 L161fs*6

QKI K134fs*14

RBM10 R186*

RNF43 G659fs*41

SOX9 Y297fs*281

SUFU P32fs*64

TBX3 A617T

TET2 P929fs*4

TSC2 splice site 138+1G>A

- Next step (s)
 - Stay the course
 - Pembrolizumab
 - Nivolumab
 - Nivolumab/ Ipilimumab
 - Other therapy
 - Other testing formal genetic counseling



- 70 year old male patient presented with vague upper abdominal and back pain 1/2017
 - Conservative management no improvement
 - EGD, colonoscopy negative
 - CT scan pancreatic mass
 - EUS biopsy adenocarcinoma
 - CA19-9: 967
- ECOG PS 1
- Family history
 - Mother had breast cancer at 42 and colon at 55, then a second breast cancer at 72
 - Mother has 6 siblings no cancer
 - Extended family history unknown
 - Ancestry: Father –Russian, Mother –Romanian. Ashkenazi Jewish on both sides

- Imaging-
 - Pancreatic mass 3 by 2.9
 - Encases SMA
 - 180 degrees interface with celiac trunk and common hepatic artery and portal SMV confluence
 - Peroneal nodule 1.7 X 1.3 cm
 - Necrotic aorto-caval lymph node 1.7 X 1.6 cm

- Next Step
 - a) Surgery
 - b) Chemotherapy
 - a) FOLFIRINOX
 - b) Gemcitabine nab-paclitaxel
 - c) Genetic counseling
 - d) Molecular profiling of tumor

- Genetic testing
- Somatic mutations for
 - BRCA1 gene
 - MSH6 gene

- Next Step
 - a) Platinum-based chemotherapy
 - b) Gemcitabine nab-paclitaxel
 - c) Pembrolizumab
 - d) PARP inhibitor
 - e) Other

- Started on pembrolizumab
 - Ca19-9 decreased from 1134 (4/17/2018) to 11 (7/25/2018)
 - Scan resolution of necrotic lymph node and peritoneal nodule, decrease size of pancreatic mass
- Duration of therapy?